HER2-Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2028

Adam Pearson, Ph.D, is an Oncology and Hematology Analyst at GlobalData in London. He offers in-depth market intelligence and data interpretation within the oncology pharmaceuticals sector. Adam completed his Cancer Research UK-funded PhD in Molecular Cancer Studies at the University of Manchester, where he studied the mechanisms whereby ERK5 regulates transcription, with a particular interest in how ERK5 promotes the development of resistance in HER2-positive breast cancer. His doctoral research resulted in publications in the International Journal of Molecular Science (IJMS), Proceedings of the National Academy of Sciences of the United States of America (PNAS) and the Annals of Oncology. Prior to this, he received an MSc in Cancer Biology from University College London and his BSc in Biomedical Sciences from the University of Manchester. He has also worked as a scientist in a Molecular Pathology Lab as part of the Imperial College NHS Healthcare Trust at Hammersmith Hospital.

Fern Barkalow, PhD, is the Senior Director of Oncology and Hematology at GlobalData in Boston. Fern has over 20 years of experience in the biopharmaceutical industry, as well as a research background in molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern then joined the database group at Incyte Pharmaceuticals where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then moved into the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs. Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine and Dentistry of New Jersey and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women’s Hospital.